The purpose of this study was to determine the usefulness of the hybrid capture HPV DNA assay, a new nonradioactive solution hybridization assay, as a diagnostic tool for human papillomavirus infection. In a total of 234 women, samples for the hybrid capture assay and polymerase chain reaction (PCR) assay were obtained by wiping a swab across the cervix and external os (either a Dacron swab or a cotton swab was used). The papanicolaou smear test (Pap smear) was carried out on all 234 women. Tissue samples for biopsy were obtained by colposcopy from 118 of the women. Fisher exact test was used for statistical analyses. Using the hybrid capture assay, HPV DNA of high-and intermediate-oncogenic-risk type was detected in 23 (13.9%) of 166 samples from women with Pap smear Class I or II, and 48 (70.6%) of 68 with Pap smear Class III, IV or V (p<0.0001). The HPV DNA type was detected in 18 (29.0%) of 62 samples from those with no evidence of cervical intraepithelial neoplasia and 44 (78.6%) of 56 with cervical intraepithelial neoplasia or squamous cell carcinoma (p<0.0001). Correlation of the test results between the hybrid capture test and PCR was determined by using the 217 samples in which both test results were available (PCR test results were not obtainable in 17 samples. When PCR is set as a gold standard, the hybrid capture test has high sensitivity (74.6%) and specificity (92.7%). These findings suggest that the hybrid capture HPV DNA assay is a useful method for diagnosing HPV infection in the clinic.
Introduction
Among microorganisms causing sexually transmitted diseases (STD), the human papillomavirus (HPV) is recognized as the major cause of cervical cancer precursor lesions1). Early detection of HPV genital tract infection is important especially in asymptomatic individuals, because the majority of individuals with HPV genital tract infection do not present visible lesions. Since serologic assays and cell cultures are not available for detecting HPV infection, HPV DNA detection assays including the polymerase chain reaction (PCR), Southern blot, dot blot and in situ hybridization become important tools in the detection of HPV infection. Of these, PCR assay and Southern blots have higher Hybrid Capture assay and PCR metod cancers and their precursor lesions1). Detection of HPV infection is important for predicting cervical cancer precursor lesions6). Since HPV infection occurs frequently concomitant with chlamydial and gonococcal infections7), examination for HPV DNA is recommended together with Chlarnydia trachomatis and Neisseria gonorrhoeae in patients suspected of having STD. Over 70 types of HPV are known, of which 18 types have been detected in specimens from the cervix3). The hybrid capture assay is a nonradioactive assay that utilizes solution hybridization. The RNA probe mixture in this kit includes all the clinically important types of HPV DNA classified as intermediate to high risk types.
Using the hybrid capture assay, Sun8) detected HPV DNA (by probe B only) in 78 (31%) of 254 samples from women with no evidence of cervical intraepithelial neoplasia and in 120 (80%) from 155 women with cervical intraepithelial neoplasia or cervical cancer. Using the same method, we detected HPV DNA in 18 (29.0%) of 62 samples from women with no evidence of cervical intraepithelial neoplasia and 44 (78.6%) of 56 samples from those with cervical intraepithelial neoplasia or cervical squamous cell carcinoma (p=0.0006). The positive rate increased as the cytological or histological abnormality increased. In a study of women who had attended STD clinic9), a 28% of the women with HPV became CIN grade 2 or 3 two years later, while 3% of women without HPV became CIN grade 2 or 3. This finding suggests that HPV infection is associated with malignant transformation of the cervical lesion. This kit may be useful for early detection of the transformation process from HPV infection, via a dysplasic stage, to invasive cancer.
Conventional HPV DNA detection methods are not widely used for clinical purpose because they require specific apparatus and equipment, involve complicated procedures, are time consuming, or are difficult to use with large numbers of clinical specimens. In contrast, the hybrid capture HPV DNA assay has several advantages over the other detection methods in terms of clinical application. A large number of clinical specimens can be tested, because it requires no special apparatus or equipment, the procedures are more convenient, and the whole assay can be completed in only three and a half hours. PCR with consensus primers detects almost all the types of HPV DNA; hybrid capture detects low-oncogenic-risk-HPV type by probe A and high-and intermediate-oncogenic-risk-HPV type by probe B. Hybrid capture had high sensitivity (74.6%) and specificity (92.7%) by counting the positive cases reacting to probe B in the present analysis [when counting the positive cases reacting with probes A and B, sensitivity was 82.0% (50/61) and specificity was 89.1% (139/156)]. Hybrid capture is a non-amplification method; however it had high sensitivity and specificity compared with PCR set as a gold standard, though 1) PCR has a significant problem of false positivity1), 2) and sometimes the PCR result is not obtainable because of the incomplete removal of inhibitory substances in the specimen. In the present study, the results of PCR could not be obtained in some cases, in most of which a cotton swab with a wooden stick was used. It is suggested that certain kinds of inhibitory substances may not be removed by the DNA preparation procedure when a cotton swab with a wooden stick is used.
Regarding hybrid capture, false negativity should be considered in the cases in which PCR appears positive and hybrid capture appears negative, because the positive result by hybrid capture can be obtained only when the concentration of HPV DNA in a sample is greater than 1.0pg/ml3). Cope (1997) reported that the sensitivity of the first generation hybrid capture tube method10), with PCR used as the standard for HPV status, was higher for specimens from women with concurrent squamous intraepithelial lesions (81.0%) than for specimens from women with normal cytology (46.7%) when the analysis was restricted to the 14 types detectable by both methods. Though our samples were not tested by the first generation hybrid capture tube method and our analysis was not restricted to the same types detectable by both methods, we had similar results; the sensitivity of hybrid capture, with PCR used as the standard for HPV status, was higher for specimens from women with Pap smear Class I or II (60.7%; 17/28) than for specimens from women with Pap smear Class III, IV or V (86.8%; 33/38). It should be borne in mind that a greater proportion of the patients with normal cytology in the total subjects makes the sensitivity lower.
In conclusion, our findings suggest that hybrid capture HPV DNA assay may become a standard detection method for diagnosing HPV infection in the clinical situation.
